http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 송영욱 ( Yeo (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
박유랑,Tae Su Chung,Young Joo Lee,송영욱,이은영,Yeo Won Sohn,Sukgil SONG,박웅양,김주한 대한의학회 2012 Journal of Korean medical science Vol.27 No.10
Infection by microorganisms may cause fatally erroneous interpretations in the biologic researches based on cell culture. The contamination by microorganism in the cell culture is quite frequent (5% to 35%). However, current approaches to identify the presence of contamination have many limitations such as high cost of time and labor, and difficulty in interpreting the result. In this paper, we propose a model to predict cell infection, using a microarray technique which gives an overview of the whole genome profile. By analysis of 62 microarray expression profiles under various experimental conditions altering cell type,source of infection and collection time, we discovered 5 marker genes, NM_005298,NM_016408, NM_014588, S76389, and NM_001853. In addition, we discovered two of these genes, S76389, and NM_001853, are involved in a Mycolplasma-specific infection process. We also suggest models to predict the source of infection, cell type or time after infection. We implemented a web based prediction tool in microarray data, named Prediction of Microbial Infection (http://www.snubi.org/software/PMI).
-
불응성 염증성 근병증 환자에 대한 Rituximab 치료
양지애 ( Ji Ae Yang ),이상진 ( Sang Jin Lee ),박준원 ( Jun Won Park ),권현미 ( Hyun Mi Kwon ),문진영 ( Jin Young Moon ),고동진 ( Dong Jin Ko ),장성혜 ( Sung Hae Chang ),박진균 ( Jin Kyun Park ),이은봉 ( Eun Bong Lee ),송영욱 ( Yeo 대한류마티스학회 2013 대한류마티스학회지 Vol.20 No.5
Objective. To assess the efficacy and safety of rituximab (RTX) on disease activity and muscle strength in patients with inflammatory myopathies refractory to conventional therapy. Methods. Four inflammatory myopathy patients who had been refractory to glucocorticoids, one or more immunosuppressive therapies and intravenous immunoglobulin were treated on an open-label basis. Each patient received two 500 mg doses of RTX 2 weeks apart in one cycle. In one patient who did not respond after the first cycle of RTX, the infusion schedule was modified by the physician. We measured muscle enzyme including CPK, LDH and assessed muscle strength individually to evaluate RTX response. Additionally anti-CD19 antibody was measured. Results. Three patients responded to the first cycle of RTX treatment with improvements in muscle enzyme and muscle strength, and then maintained physical function over the duration of several infusion cycles. In one patient, muscle enzyme did not decrease after the first cycle of RTX, and a high dose glucocorticoid was given. After modifying the treatment schedule with monthly RTX infusion, his muscle enzyme level and muscle strength improved. Anti-CD19 antibody decreased after RTX generally, but responses were variable. Herpes zoster infection occurred in two patients. Conclusion. Rituximab may be a therapeutic choice in refractory inflammatory myopathy. However a further trial is needed to confirm the efficacy and prove the safety.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
